May 2024
Discussing RA: May 2024
Join Professor Iain McInnes and guests Professor Janet Pope and Dr Sofia Ramiro for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers that investigated the long-term safety of JAK inhibitors from Phase 3 trials. In our first paper, Maya Buch and colleagues examined extended MACE endpoints with tofacitinib versus TNFi. Our second paper is from Gerd Burmester and colleagues present long-term efficacy and safety data for upadacitinib through five years. To access detailed summary slides for the papers discussed today, visit imidforum.com.
Discussing PsA: Bimekizumab therapy in PsA
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the latest publication by Su, et al. and discuss the latest in bimekizumab therapy in PsA.
IMID Author Interview: Dr Blanca Hernández-Cruz, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Blanca Hernández-Cruz, a rheumatologist at Virgen Macarena University Hospital in Seville, as they discuss her recent paper ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry’.
IMID Author Interview: Dorthe Berthelsen, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Dorthe Berthelsen, a PhD student and physiotherapist at the Parker Institute in Copenhagen and at the University of Southern Denmark, as they discuss her recent paper ‘“I couldn't carry on taking a drug like that”: A qualitative study of patient perspectives on side effects from rheumatology drugs.’
Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar
Webinar Highlights Podcast: Join Professor Iain McInnes and Associate Professor Laura Coates on the Immune-Mediated Inflammatory Disease Forum in their discussion on the recent webinar “Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar”. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the pathophysiology of IL-23 inhibitors compared with TNF and IL-17 inhibitor therapies, and the relationship between IL-23 inhibitor MOA variation and real-world patient data.
IMID Author Interview: Dr Jake Weddell, 2024
Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jake Weddell, an academic rheumatology trainee at Leeds Teaching Hospitals NHS Trust, as they discuss his recent paper ‘Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.’